| Name: | Description: | Size: | Format: | |
|---|---|---|---|---|
| 700.49 KB | Adobe PDF |
Authors
Abstract(s)
Esta revisão foi elaborada seguindo as diretrizes PRISMA usando a seguinte
pergunta PICO: “Os SNPs presentes em vias de reparação genética apresentam
impacto no resultado clínico do tratamento antineoplásico em pacientes
portadores de cancro oral?” Foi realizada busca nos bancos de dados PubMed
e Web of Science, usando as seguintes palavras-chave MeSH (incluindo termos
sinónimos e termos hierarquicamente incluídos nos termos listados):
(Polymorphism, Single Nucleotide) AND ((DNA repair) OR (DNA repair
enzymes)) AND ((mouth neoplasms) OR (Squamous Cell Carcinoma of Head
and Neck)) AND ((drug therapy) OR (antineoplastic agents) OR (radiotherapy)
OR (chemoradiotherapy)). A busca na literatura resultou em 142 estudos e, após
a aplicação dos critérios de seleção e remoção dos duplicados, 7 estudos foram
incluídos nesta revisão. Na via de reparação por excisão de bases (BER) foram
identificados 6 SNPs (rs1760944, rs3219489, rs1052133, rs1799782, rs25489 e
rs25487) em 4 genes (APEX1, MUTYH, OGG1, XRCC1), com 2 SNPs no gene
XRCC1 não apresentando associação significante (rs25487 e rs25489) os
demais estão relacionados com o resultado do tratamento antineoplásico nos
pacientes com cancro oral. O gene MLH1 foi avaliado através de dois SNPs
(rs1800734 e rs1540354). Apenas o rs1800734 apresentou associação com
sobrevida livre da doença e sobrevida global. O conhecimento sobre esses SNPs
pode ajudar a direcionar melhor a estratégia de tratamento, individualizando-o
de acordo com a resposta esperada em decorrência do perfil genético do
paciente.
This review was developed following the PRISMA guidelines using the following PICO question: “Do SNPs present in genetic repair pathways impact the clinical outcome of anticancer treatment in patients with oral cancer?” A search was performed in PubMed and Web of Science databases, using the following MeSH keywords (including synonyms and hierarchically included terms): (Polymorphism, Single Nucleotide) AND ((DNA repair) OR (DNA repair enzymes)) AND (( mouth neoplasms) OR (Squamous Cell Carcinoma of Head and Neck)) AND ((drug therapy) OR (antineoplastic agents) OR (radiotherapy) OR (chemoradiotherapy)).The literature search resulted in 142 studies and, after application of the selection criteria and removal of duplicates , 7 studies were included in this review. In the base excision repair (BER) pathway, 6 SNPs (rs1760944, rs3219489, rs1052133, rs1799782, rs25489 and rs25487) were identified in 4 genes (APEX1, MUTYH, OGG1, XRCC1), with 2 SNPs in the XRCC1 gene did not show a significant association (rs25487 and rs25489) the others are related to the outcome of the anticancer treatment in patients with oral cancer. The MLH1 gene was evaluated through two SNPs (rs1800734 and rs1540354). Only rs1800734 showed an association. with free survival disease and overall survival. Knowledge about these SNPs can help to better target the treatment strategy, individualizing it according to the expected response as a result of the patient's genetic profile.
This review was developed following the PRISMA guidelines using the following PICO question: “Do SNPs present in genetic repair pathways impact the clinical outcome of anticancer treatment in patients with oral cancer?” A search was performed in PubMed and Web of Science databases, using the following MeSH keywords (including synonyms and hierarchically included terms): (Polymorphism, Single Nucleotide) AND ((DNA repair) OR (DNA repair enzymes)) AND (( mouth neoplasms) OR (Squamous Cell Carcinoma of Head and Neck)) AND ((drug therapy) OR (antineoplastic agents) OR (radiotherapy) OR (chemoradiotherapy)).The literature search resulted in 142 studies and, after application of the selection criteria and removal of duplicates , 7 studies were included in this review. In the base excision repair (BER) pathway, 6 SNPs (rs1760944, rs3219489, rs1052133, rs1799782, rs25489 and rs25487) were identified in 4 genes (APEX1, MUTYH, OGG1, XRCC1), with 2 SNPs in the XRCC1 gene did not show a significant association (rs25487 and rs25489) the others are related to the outcome of the anticancer treatment in patients with oral cancer. The MLH1 gene was evaluated through two SNPs (rs1800734 and rs1540354). Only rs1800734 showed an association. with free survival disease and overall survival. Knowledge about these SNPs can help to better target the treatment strategy, individualizing it according to the expected response as a result of the patient's genetic profile.
Description
Keywords
Polimorfismo de um único nucleótido Quimioterapia Radioterapia Cancro oral Polymorphism Single nucleotide Radiotherapy Chemoradiotherapy Mouth neoplasms